Forte Biosciences, Inc.
FBRX
$6.32
-$0.34-5.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.12M | 2.76M | 7.08M | 3.45M | 2.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.35M | 8.63M | 12.82M | 7.80M | 6.38M |
| Operating Income | -7.35M | -8.63M | -12.82M | -7.80M | -6.38M |
| Income Before Tax | -7.16M | -8.39M | -12.51M | -7.42M | -5.87M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.16M | -8.39M | -12.51M | -7.42M | -5.87M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.16M | -8.39M | -12.51M | -7.42M | -5.87M |
| EBIT | -7.35M | -8.63M | -12.82M | -7.80M | -6.38M |
| EBITDA | -7.34M | -8.62M | -12.81M | -7.80M | -6.38M |
| EPS Basic | -1.17 | -4.54 | -6.78 | -4.03 | -3.18 |
| Normalized Basic EPS | -0.73 | -2.84 | -4.24 | -2.52 | -1.99 |
| EPS Diluted | -1.17 | -4.54 | -6.78 | -4.03 | -3.18 |
| Normalized Diluted EPS | -0.73 | -2.84 | -4.24 | -2.52 | -1.99 |
| Average Basic Shares Outstanding | 6.13M | 1.85M | 1.85M | 1.84M | 1.85M |
| Average Diluted Shares Outstanding | 6.13M | 1.85M | 1.85M | 1.84M | 1.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |